The Patient Access Network (PAN) Foundation and Multiple Sclerosis Association of America (MSAA) today announced they are launching a new alliance to offer a broad range of support for people […]

The Multiple Sclerosis Association of America (MSAA) is pleased to announce its newest member of its Board of Directors, Ira M. Levee of West Orange, New Jersey. Mr. Levee is […]

The Multiple Sclerosis Association of America (MSAA), a national nonprofit organization and leading resource for the MS community, and Antidote Technologies, a digital health company, have announced a partnership to increase awareness of MS clinical trials and enable people to easily access this important information. The Antidote Match clinical trial search tool will now be available on MSAA’s website, allowing visitors to find trials that are right for them or their loved ones in minutes, just by answering a few questions.

The Multiple Sclerosis Association of America (MSAA) is pleased to announce that John McCorry has been elected as the Chairman of their Board of Directors. Mr. McCorry is Senior Executive […]

The results from three Phase III studies of the experimental medication Ocrevus™ (ocrelizumab) were published in the December 21, 2016 online issue of the New England Journal of Medicine (NEJM). […]

On December 20, 2016, Genentech, a member of the Roche group, announced that the United States Food and Drug Administration (FDA) had extended the review period of Ocrevus™ (ocrelizumab) for […]